Updates to Systemic Therapy for Differentiated Thyroid Cancer

Presented by:
Lori J. Wirth
Search for other papers by Lori J. Wirth in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 23: Issue Supplement
Online Publication Date:
27 May 2025
DOI:
https://doi.org/10.6004/jnccn.2025.5015
Restricted access

Radioiodine-refractory differentiated thyroid cancer (DTC) encompasses a biologically diverse group of tumors that, once unresponsive to radioactive iodine, require systemic therapy decisions driven by timing, disease kinetics, molecular alterations, and patient preferences. Landmark trials have established multikinase inhibitors as the backbone of therapy for progressive radioiodine-refractory DTC, with lenvatinib emerging as the preferred agent. At the same time, next-generation sequencing has revealed a high prevalence of actionable genomic drivers in thyroid cancer, with RET and NTRK fusions as well as BRAF mutations offering opportunities for targeted therapy. This presentation discussed updated clinical strategies and NCCN Guidelines–aligned recommendations for the management of patients with advanced radioiodine-refractory DTC, based on recent data and evolving paradigms.

Disclosures: Dr. Wirth has disclosed receiving consulting fees from AbbVie, Inc., Bayer HealthCare, Bicara Therapeutics Inc., Coherus BioSciences, Eisai Inc., Eli Lilly and Company, EMD Serono, Inc., Exelixis, Inc., Illumina, Inc., Merck & Co., Inc., Nested Therapeutics, PDS Biotechnology, Replimune, and Tubulis Gmbh; and serving as a scientific advisor for Eisai Inc., Eli Lilly and Company, and Ellipses Pharma.

Correspondence: Lori J. Wirth, MD, Mass General Cancer Center, 55 Fruit Street, Boston, MA 02114. Email: lwirth@mgh.harvard.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 2019;29:461–470.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Seo GH, Cho YY, Chung JH, et al. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid 2015;25:927–934.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Brose MS, Smit JWA, Lin C, et al. Multikinase inhibitors for the treatment of asymptomatic radioactive iodine-refractory differentiated thyroid cancer: global noninterventional study (RIFTOS MKI). Thyroid 2022;32:1059–1068.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621–630.

  • 5.

    Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319–328.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Taylor MH, Takahashi S, Capdevila J, et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 2021;31:1226–1234.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Tahara M, Kiyota N, Hoff AO, et al. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 2021;147:51–57.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Brose MS, Panaseykin Y, Konda B, et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 2022;107:776–787.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial. Cancer 2022;128:4203–4212.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23:703–713.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Pekova B, Sykorova V, Dvorakova S, et al. RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid 2020;30:1771–1780.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Heilmann AM, Holmes O, Wang K, et al. Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. Oncologist 2017;22:255–263.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Ricarte-Filho JC, Li S, Garcia-Rendueles MER, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest 2013;123:4935–4944.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Chu YH, Wirth LJ, Farahani AA, et al. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Mod Pathol 2020;33:2458–2472.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825–835.

  • 16.

    Rolfo C, Ruiz R, Giovannetti E, et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs 2015;24:1493–1500.

  • 17.

    Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021;9:491–501.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Busaidy NL, Konda B, Wei L, et al. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 2022;32:1184–1192.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    French JD, Haugen BR, Worden FP, et al. Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin Cancer Res 2024;30:3757–3767.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2025 by the National Comprehensive Cancer Network 2025
Article Category:
Abstract
Print Publication Date:
01 May 2025
Online Publication Date:
27 May 2025

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 321 321 321
PDF Downloads 122 122 122
EPUB Downloads 0 0 0